Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2021-07-15 Investor Presentation
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
COVID ARDS Trial Respiratory Outcomes Presented 2 pages 175.4KB
Investor Presentation Classification · 95% confidence The document is a press release announcing the presentation of clinical trial results for a COVID-19 ARDS treatment by Mesoblast at a scientific conference. It includes detailed clinical outcome data and trial information but does not contain comprehensive financial statements or regulatory filings. It is not an earnings release, annual report, or interim report. It is also not a call transcript, board management change, or capital update. The document is a corporate announcement of clinical trial results presented at a conference, which aligns best with an Investor Presentation (IP) as it focuses on clinical data and company strategy related to product development and partnerships. The document length (8507 characters) and content support this classification rather than a brief announcement or regulatory filing.
2021-07-15 English
Appendix 3Y - Change of Director's Interest Notice 3 pages 287.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a director, including number of shares and options held before and after the change, nature of the change, and dates. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document is not an announcement of a report, nor a full financial report, but a specific regulatory filing about director share transactions.
2021-07-13 English
6-K
Regulatory Filings
2021-07-09 English
Appendix 3G 18 pages 396.5KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G Notification of issue, conversion or payment up of unquoted equity securities' and is a form used to notify the ASX about the issuance or conversion of unquoted securities, particularly under employee incentive schemes. It contains detailed structured questions about the securities issued, dates, and related information. There is no financial performance data, earnings information, or management discussion. The document is a regulatory announcement about securities issuance and conversions, not a financial report or earnings release. This type of filing corresponds to a Share Issue/Capital Change announcement, as it relates to new securities issued or converted.
2021-07-06 English
6-K
Regulatory Filings
2021-07-02 English
Mesoblast Update on Chronic Low Back Pain Program 3 pages 189.6KB
Capital/Financing Update Classification · 95% confidence The document is a press release from Mesoblast providing an update on their clinical program for chronic low back pain due to degenerative disc disease. It discusses regulatory strategy, clinical trial results, collaboration agreements, and forward-looking statements. There are no financial statements, detailed financial performance data, nor is this a transcript of a call or a regulatory filing with certifications. The document is an update on clinical and regulatory progress and partnership milestones, typical of a Capital/Financing Update or strategic business update. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or governance report. Given the focus on regulatory meetings, clinical trial progress, and milestone payments, the best fitting category is Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2021-06-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.